Halozyme Therapeutics Total Long Term Liabilities 2010-2024 | HALO

Halozyme Therapeutics total long term liabilities for the quarter ending September 30, 2024 were $1.557B, a 1.85% increase year-over-year.

  • Halozyme Therapeutics total long term liabilities for 2023 were $1.537B, a 0.26% decline from 2022.
  • Halozyme Therapeutics total long term liabilities for 2022 were $1.541B, a 94.97% increase from 2021.
  • Halozyme Therapeutics total long term liabilities for 2021 were $0.79B, a 10448.97% increase from 2020.

Halozyme Therapeutics Total Long Term Liabilities 2010-2024 | HALO

  • Halozyme Therapeutics total long term liabilities for 2023 were $1.537B, a 0.26% decline from 2022.
  • Halozyme Therapeutics total long term liabilities for 2022 were $1.541B, a 94.97% increase from 2021.
  • Halozyme Therapeutics total long term liabilities for 2021 were $0.79B, a 10448.97% increase from 2020.